Free Trial Information
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

Propelled by new insights into disease biology, the clinical pipeline for ALS has grown to at least 43 programs attacking the disease from a dozen different directions. With six of those programs in Phase...
Read More
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

...MPO) inhibitor MPO Neuroinflammation Clene Nanomedicine Inc. CNM-Au8 Orally administered nanocrystalline gold suspension NA Neuroprotection Implicit Biosciences...
...she said. Tackling innate immune response Zilucoplan from Ra Pharmaceutical Inc. (NASDAQ:RARX) and IC14 from Implicit Biosciences...
...in both controlling disease before symptoms appear and determining its rate of progression.” Garry Redlich, Implicit Biosciences...
Read More
BioCentury | Sep 27, 2019
Product Development

Lessons from Healey ALS on how to build platform trials quickly

...convincing answer that the platform study will offer. I can’t see any alternative.” Garry Redlich, Implicit Biosciences...
...faster data from a platform trial,” Garry Redlich, CEO and managing director of participating company Implicit Biosciences...
...MPO) inhibitor MPO Neuroinflammation Clene Nanomedicine Inc. CNM-Au8 Orally administered nanocrystalline gold suspension NA Neuroprotection Implicit Biosciences...
Read More
BioCentury | Sep 24, 2019
Clinical News

First adaptive platform trial in ALS could speed development, find new biomarkers

An adaptive platform trial for ALS launched by Mass General could find new biomarkers to serve as surrogate endpoints or predictors of response in the pivotal trial and future studies. Researchers at Massachusetts General Hospital’s...
Read More
BioCentury | Jun 13, 2013
Distillery Therapeutics

Indication: Infectious disease

...antigens. Next steps could include testing the antibacterial effects in additional models of bacterial infection. Implicit Biosciences Pty. Ltd.'s...
Read More
BioCentury | Mar 2, 2009
Company News

Implicit Biosciences, Eli Lilly deal

...oglufanide, a dipeptide immunomodulator in Phase II testing to treat various indications, including respiratory conditions. Implicit Biosciences Pty. Ltd....
Read More
BioCentury | Oct 29, 2007
Company News

Implicit Bioscience Pty. Ltd., U.S. Department of Defense infectious news

Implicit will receive $16.3 million over 37 months from the DoD to develop oglufanide (IM862) to treat intracellular bacterial diseases, including melioidosis, a type of pneumonia. The dipeptide immunomodulator is in Phase II testing for...
Read More
BioCentury | Sep 3, 2007
Clinical News

Oglufanide disodium: Phase IIa started

...trial in 20 patients to evaluate 0.1 mg/day of intranasal oglufanide disodium for 21 days. Implicit Biosciences Pty. Ltd....
Read More
BioCentury | Mar 26, 2007
Company News

Implicit Bioscience Pty. Ltd. management update

Implicit Bioscience Pty. Ltd. , Brisbane, Australia Business: Infectious Hired: Timothy Axtelle as VP of R&D, formerly director of therapeutic development at Icos Corp. WIR Staff...
Read More
Items per page:
1 - 9 of 9
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

Propelled by new insights into disease biology, the clinical pipeline for ALS has grown to at least 43 programs attacking the disease from a dozen different directions. With six of those programs in Phase...
Read More
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

...MPO) inhibitor MPO Neuroinflammation Clene Nanomedicine Inc. CNM-Au8 Orally administered nanocrystalline gold suspension NA Neuroprotection Implicit Biosciences...
...she said. Tackling innate immune response Zilucoplan from Ra Pharmaceutical Inc. (NASDAQ:RARX) and IC14 from Implicit Biosciences...
...in both controlling disease before symptoms appear and determining its rate of progression.” Garry Redlich, Implicit Biosciences...
Read More
BioCentury | Sep 27, 2019
Product Development

Lessons from Healey ALS on how to build platform trials quickly

...convincing answer that the platform study will offer. I can’t see any alternative.” Garry Redlich, Implicit Biosciences...
...faster data from a platform trial,” Garry Redlich, CEO and managing director of participating company Implicit Biosciences...
...MPO) inhibitor MPO Neuroinflammation Clene Nanomedicine Inc. CNM-Au8 Orally administered nanocrystalline gold suspension NA Neuroprotection Implicit Biosciences...
Read More
BioCentury | Sep 24, 2019
Clinical News

First adaptive platform trial in ALS could speed development, find new biomarkers

An adaptive platform trial for ALS launched by Mass General could find new biomarkers to serve as surrogate endpoints or predictors of response in the pivotal trial and future studies. Researchers at Massachusetts General Hospital’s...
Read More
BioCentury | Jun 13, 2013
Distillery Therapeutics

Indication: Infectious disease

...antigens. Next steps could include testing the antibacterial effects in additional models of bacterial infection. Implicit Biosciences Pty. Ltd.'s...
Read More
BioCentury | Mar 2, 2009
Company News

Implicit Biosciences, Eli Lilly deal

...oglufanide, a dipeptide immunomodulator in Phase II testing to treat various indications, including respiratory conditions. Implicit Biosciences Pty. Ltd....
Read More
BioCentury | Oct 29, 2007
Company News

Implicit Bioscience Pty. Ltd., U.S. Department of Defense infectious news

Implicit will receive $16.3 million over 37 months from the DoD to develop oglufanide (IM862) to treat intracellular bacterial diseases, including melioidosis, a type of pneumonia. The dipeptide immunomodulator is in Phase II testing for...
Read More
BioCentury | Sep 3, 2007
Clinical News

Oglufanide disodium: Phase IIa started

...trial in 20 patients to evaluate 0.1 mg/day of intranasal oglufanide disodium for 21 days. Implicit Biosciences Pty. Ltd....
Read More
BioCentury | Mar 26, 2007
Company News

Implicit Bioscience Pty. Ltd. management update

Implicit Bioscience Pty. Ltd. , Brisbane, Australia Business: Infectious Hired: Timothy Axtelle as VP of R&D, formerly director of therapeutic development at Icos Corp. WIR Staff...
Read More
Items per page:
1 - 9 of 9